Calcific Aortic Valve Stenosis (CAVS) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: CC2AAE70C64EEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Calcific Aortic Valve Stenosis (CAVS) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Calcific Aortic Valve Stenosis (CAVS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Calcific Aortic Valve Stenosis (CAVS) Understanding

The DelveInsight Calcific Aortic Valve Stenosis (CAVS) epidemiology report gives a thorough understanding of the Calcific Aortic Valve Stenosis (CAVS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Calcific Aortic Valve Stenosis (CAVS) in the US, Europe, and Japan. The report covers the detailed information of the Calcific Aortic Valve Stenosis (CAVS) epidemiology scenario in seven major countries (US, EU5, and Japan).

Calcific Aortic Valve Stenosis (CAVS) Epidemiology Perspective by DelveInsight

The Calcific Aortic Valve Stenosis (CAVS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Calcific Aortic Valve Stenosis (CAVS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Calcific Aortic Valve Stenosis (CAVS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Calcific Aortic Valve Stenosis (CAVS) Detailed Epidemiology Segmentation

The Calcific Aortic Valve Stenosis (CAVS) epidemiology covered in the report provides historical as well as forecasted Calcific Aortic Valve Stenosis (CAVS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Calcific Aortic Valve Stenosis (CAVS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Calcific Aortic Valve Stenosis (CAVS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Calcific Aortic Valve Stenosis (CAVS) Epidemiology Report and Model provide an overview of the global trends of Calcific Aortic Valve Stenosis (CAVS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Calcific Aortic Valve Stenosis (CAVS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Calcific Aortic Valve Stenosis (CAVS)
• The report provides the segmentation of the Calcific Aortic Valve Stenosis (CAVS) epidemiology

Report Highlights

• 11-year Forecast of Calcific Aortic Valve Stenosis (CAVS) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Calcific Aortic Valve Stenosis (CAVS)
• Cases of Calcific Aortic Valve Stenosis (CAVS) by Mutation Types
• Calcific Aortic Valve Stenosis (CAVS) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Calcific Aortic Valve Stenosis (CAVS)?
• What are the key findings pertaining to the Calcific Aortic Valve Stenosis (CAVS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Calcific Aortic Valve Stenosis (CAVS) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Calcific Aortic Valve Stenosis (CAVS)?
• What are the currently available treatments of Calcific Aortic Valve Stenosis (CAVS)?

Reasons to buy

The Calcific Aortic Valve Stenosis (CAVS) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Calcific Aortic Valve Stenosis (CAVS) market
• Quantify patient populations in the global Calcific Aortic Valve Stenosis (CAVS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Calcific Aortic Valve Stenosis (CAVS) therapeutics in each of the markets covered
• Understand the magnitude of Calcific Aortic Valve Stenosis (CAVS) population by its epidemiology
• The Calcific Aortic Valve Stenosis (CAVS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF CALCIFIC AORTIC VALVE STENOSIS (CAVS)

3. CALCIFIC AORTIC VALVE STENOSIS (CAVS): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Calcific Aortic Valve Stenosis (CAVS) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Calcific Aortic Valve Stenosis (CAVS) Treatment and Management
6.2. Calcific Aortic Valve Stenosis (CAVS) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in 7MM (2019-2032)
Table 2: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in the United States (2019-2032)
Table 4: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Germany (2019-2032)
Table 6: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in France (2019-2032)
Table 8: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Italy (2019-2032)
Table 10: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Spain (2019-2032)
Table 12: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in the United Kingdom (2019-2032)
Table 14: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Japan (2019-2032)
Table 16: Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in 7MM (2019-2032)
Figure 2 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in the United States (2019-2032)
Figure 4 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Germany (2019-2032)
Figure 6 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in France (2019-2032)
Figure 8 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Italy (2019-2032)
Figure 10 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Spain (2019-2032)
Figure 12 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Calcific Aortic Valve Stenosis (CAVS) Epidemiology in Japan (2019-2032)
Figure 16 Calcific Aortic Valve Stenosis (CAVS) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report